DDMAC To Cornerstone: Zyflo CR Promotions Need Current Safety Labeling
Executive Summary
An FDA advertising violation letter for Cornerstone Therapeutics' asthma therapy Zyflo CR should serve to remind industry that providing outdated safety labeling with promotions is a sure way to draw the agency's regulatory scrutiny
You may also be interested in...
FDA Declares Pox On Both Houses In Enforcement Letters For Curosurf, Infasurf
In separate “notice of violation” letters issued Oct. 31 but posted several days apart, FDA rejected superiority claims on the part of Cornerstone Therapeutics and Ony for their respiratory distress syndrome drugs.
"Bad CME" Program May Be Developed By FDA
Agency asks physicians to report instances of off-label promotion made during continuing medical education classes.
DDMAC's Latest Exhibit Hall Citation Is Vectibix; Firms Try Multiple Ways To Avoid FDA At Trade Shows
Amgen rep's description of KRAS information as predictive of response to the colorectal cancer drug during a ASHP meeting draws a notice of violation from FDA.